Market Cap 1.17B
Revenue (ttm) 606.88M
Net Income (ttm) -225.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -37.19%
Debt to Equity Ratio 0.22
Volume 5,180,700
Avg Vol 3,655,420
Day's Range N/A - N/A
Shares Out 746.33M
Stochastic %K 42%
Beta 1.50
Analysts Sell
Price Target $2.67

Company Profile

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 305 575 4100
Address:
4400 Biscayne Boulevard, Miami, United States
Gasbagger
Gasbagger Sep. 13 at 4:27 PM
$OPK Opposition to Teva chairman's jet expenses. Some things never change. There is Nobody to stop Frost ,since he calls all the shots at Opko.
0 · Reply
tymtested
tymtested Sep. 12 at 7:53 PM
$OPK on equivalent daily average, opko buys back 150,000 shares or about 6% of the stock traded. Even more impactful when considering the float is about 50% of outstanding shares.
0 · Reply
Gasbagger
Gasbagger Sep. 12 at 7:44 PM
$OPK Speaking at the Wells Fargo Healthcare Conference, President and Vice Chairman Elias Zerhouni said,a GLP-1/glucagon candidate in Phase I development.**OPK-8801001**,is at the investigational new drug stage and expects to enter clinical trials in the following month.A **CAR-T program,** a first clinical trial is expected at the end of the year or early next year.MDX-2001,with potential results expected early next year.OPKO expects Merck to make a decision on how to proceed in the near term, he said.He added that OPKO expects to pursue additional partnerships because it does not intend to independently fund every program through later stages. In every statement Zerhouni made he said EXPECTS. That is not definite. So it seems everything has been at a standstill for quite sometime . So what has 35 MILLION in R&D every quarter being spent on ?
0 · Reply
tymtested
tymtested Sep. 12 at 7:23 PM
$OPK OPKO’s utilization of nondilutive financing is a good indication they believe stock price appreciation is near and frost didn’t want to dilute it. Also ,opko may want to run up the price fairly soon,(after they buyback) to use higher priced shares to buy COCP.
0 · Reply
tradertrash
tradertrash Sep. 11 at 8:30 PM
$OPK always tomorrow... for some reason 🙄 they never can deliver today❓ ray & hgh are successful, it's just sh never get to share in that success, but u can bet they never miss a raise or bonus or stock option, for a complete failure to sh, it's been years ive heard that tomorrow bs, they just keep funding, without showing any return for sh, gets old, same old sh*t, rinse & repeat
1 · Reply
tymtested
tymtested Sep. 11 at 7:24 PM
$OPK opko will retain 100% of its royalties on mazdutide once LLY launches mazdutide in other countries outside of china. HUGE coming opportunity!
0 · Reply
Gasbagger
Gasbagger Sep. 11 at 6:25 PM
$OPK Everything Opko has done has been a failure for Shareholders,but yet ,Frost and Friends keep reaping big pay days. From all of his self serving investments ,Cocp,Entx ,Vbiv,Shareholders never received ONE SHARE of anything. Frost now wants you to believe in ModeX as all the cash is disappearing.
0 · Reply
Sierradude
Sierradude Sep. 11 at 5:32 PM
$OPK 12.5 mil a year? At that rate they can pay their Israeli tax bill in 20 years.... don't piss on my back and tell me its raining.....
1 · Reply
tymtested
tymtested Sep. 11 at 4:52 PM
$OPK i just hope opko can complete the stock buyback at these low prices.
0 · Reply
tymtested
tymtested Sep. 11 at 4:50 PM
$OPK if opko were to announce that bioref labs were generating $12.5M earns annually the stock would probably explode!!whats the difference?!?
0 · Reply
Latest News on OPK
Cocrystal Pharma announces $5M investment from Opko Health

2026-08-03T11:25:21.000Z - 5 weeks ago

Cocrystal Pharma announces $5M investment from Opko Health

COCP


Opko Health sees Q3 revenue $131M-$142M, consensus $134.65M

2026-07-27T20:50:40.000Z - 6 weeks ago

Opko Health sees Q3 revenue $131M-$142M, consensus $134.65M


Opko Health sees FY26 revenue $560M-$585M, consensus $536.88M

2026-07-27T20:50:27.000Z - 6 weeks ago

Opko Health sees FY26 revenue $560M-$585M, consensus $536.88M


Opko Health reports Q2 EPS (1c), one estimate (11c)

2026-07-27T20:45:11.000Z - 6 weeks ago

Opko Health reports Q2 EPS (1c), one estimate (11c)


OPKO Health Earnings Call Transcript: Q2 2026

Jul 27, 2026, 4:30 PM EDT - 6 weeks ago

OPKO Health Earnings Call Transcript: Q2 2026


OPKO Health Earnings release: Q2 2026

Jul 27, 2026, 4:30 PM EDT - 6 weeks ago

OPKO Health Earnings release: Q2 2026


OPKO Health Quarterly report: Q2 2026

Jul 27, 2026, 4:30 PM EDT - 6 weeks ago

OPKO Health Quarterly report: Q2 2026


OPKO Health Transcript: AGM 2026

Jun 18, 2026, 10:00 AM EDT - 2 months ago

OPKO Health Transcript: AGM 2026


OPKO Health Proxy statement: Proxy filing

May 15, 2026, 8:00 AM EDT - 4 months ago

OPKO Health Proxy statement: Proxy filing


OPKO Health Slides: Corporate presentation

May 8, 2026, 7:00 AM EDT - 4 months ago

OPKO Health Slides: Corporate presentation


OPKO Health Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

OPKO Health Proxy statement: Proxy filing


OPKO Health Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

OPKO Health Proxy statement: Proxy filing


OPKO Health Earnings Call Transcript: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 4 months ago

OPKO Health Earnings Call Transcript: Q1 2026


OPKO Health Earnings release: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 4 months ago

OPKO Health Earnings release: Q1 2026


OPKO Health Quarterly report: Q1 2026

Apr 28, 2026, 4:30 PM EDT - 4 months ago

OPKO Health Quarterly report: Q1 2026


OPKO Health Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 6 months ago

OPKO Health Earnings Call Transcript: Q4 2025


OPKO Health Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 6 months ago

OPKO Health Annual report: Q4 2025


OPKO Health Earnings release: Q4 2025

Feb 26, 2026, 4:30 PM EST - 6 months ago

OPKO Health Earnings release: Q4 2025


OPKO Health Slides: Corporate presentation

Nov 26, 2025, 7:00 AM EST - 9 months ago

OPKO Health Slides: Corporate presentation


Opko Health initiated with a Neutral at JPMorgan

2025-11-20T09:50:09.000Z - 9 months ago

Opko Health initiated with a Neutral at JPMorgan


Opko Health downgraded to Hold from Buy at Jefferies

2025-10-30T20:10:16.000Z - 10 months ago

Opko Health downgraded to Hold from Buy at Jefferies


Opko Health reports Q3 EPS 3c, consensus (5c)

2025-10-29T20:36:22.000Z - 10 months ago

Opko Health reports Q3 EPS 3c, consensus (5c)


OPKO Health Earnings Call Transcript: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 10 months ago

OPKO Health Earnings Call Transcript: Q3 2025


OPKO Health Quarterly report: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 10 months ago

OPKO Health Quarterly report: Q3 2025


OPKO Health Earnings release: Q3 2025

Oct 29, 2025, 4:30 PM EDT - 10 months ago

OPKO Health Earnings release: Q3 2025


Opko Health’s ModeX Therapeutics begins trial of MDX2004

2025-10-28T12:21:29.000Z - 10 months ago

Opko Health’s ModeX Therapeutics begins trial of MDX2004


Opko Health management to meet with Barrington

2025-09-22T12:00:42.000Z - 11 months ago

Opko Health management to meet with Barrington


OPKO Health Earnings Call Transcript: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings Call Transcript: Q2 2025


OPKO Health Quarterly report: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Quarterly report: Q2 2025


OPKO Health Earnings release: Q2 2025

Jul 31, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings release: Q2 2025


NextPlat Issues Interim CEO Update Shareholder Letter

Jun 30, 2025, 8:01 AM EDT - 1 year ago

NextPlat Issues Interim CEO Update Shareholder Letter

NXPL


OPKO Health Earnings Call Transcript: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings Call Transcript: Q1 2025


OPKO Health Quarterly report: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Quarterly report: Q1 2025


OPKO Health Earnings release: Q1 2025

Apr 30, 2025, 4:30 PM EDT - 1 year ago

OPKO Health Earnings release: Q1 2025


OPKO and Entera partner to develop obesity pill

Mar 17, 2025, 8:57 AM EDT - 1 year ago

OPKO and Entera partner to develop obesity pill


OPKO Health Proxy statement: Proxy Filing

Mar 14, 2025, 8:00 AM EDT - 1 year ago

OPKO Health Proxy statement: Proxy Filing


OPKO Health Proxy statement: Proxy Filing

Mar 14, 2025, 8:00 AM EDT - 1 year ago

OPKO Health Proxy statement: Proxy Filing


OPKO Health Earnings Call Transcript: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Earnings Call Transcript: Q4 2024


OPKO Health Annual report: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Annual report: Q4 2024


OPKO Health Earnings release: Q4 2024

Feb 27, 2025, 4:30 PM EST - 1 year ago

OPKO Health Earnings release: Q4 2024


OPKO Health Slides: FY 2025

Jan 15, 2025, 6:00 PM EST - 1 year ago

OPKO Health Slides: FY 2025


OPKO Health Earnings Call Transcript: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Earnings Call Transcript: Q3 2024


OPKO Health Quarterly report: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Quarterly report: Q3 2024


OPKO Health Earnings release: Q3 2024

Nov 7, 2024, 4:30 PM EST - 1 year ago

OPKO Health Earnings release: Q3 2024


OPKO Health Proxy statement: Proxy Filing

Aug 30, 2024, 8:00 AM EDT - 2 years ago

OPKO Health Proxy statement: Proxy Filing


OPKO Health Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings Call Transcript: Q2 2024


OPKO Health Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Quarterly report: Q2 2024


OPKO Health Earnings release: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings release: Q2 2024


OPKO Health Earnings Call Transcript: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings Call Transcript: Q1 2024


OPKO Health Quarterly report: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Quarterly report: Q1 2024


OPKO Health Earnings release: Q1 2024

May 7, 2024, 4:30 PM EDT - 2 years ago

OPKO Health Earnings release: Q1 2024


OPKO Health Proxy statement: Proxy Filing

Feb 29, 2024, 7:00 AM EST - 2 years ago

OPKO Health Proxy statement: Proxy Filing


OPKO Health Earnings Call Transcript: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Earnings Call Transcript: Q4 2023


OPKO Health Annual report: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Annual report: Q4 2023


OPKO Health Earnings release: Q4 2023

Feb 27, 2024, 4:30 PM EST - 2 years ago

OPKO Health Earnings release: Q4 2023


OPKO Health Proxy statement: Proxy Filing

Feb 16, 2024, 7:00 AM EST - 2 years ago

OPKO Health Proxy statement: Proxy Filing


OPKO Health Earnings Call Transcript: Q3 2023

Nov 6, 2023, 4:30 PM EST - 2 years ago

OPKO Health Earnings Call Transcript: Q3 2023


OPKO Health Quarterly report: Q3 2023

Nov 6, 2023, 4:30 PM EST - 2 years ago

OPKO Health Quarterly report: Q3 2023


OPKO Health Earnings release: Q3 2023

Nov 6, 2023, 4:30 PM EST - 2 years ago

OPKO Health Earnings release: Q3 2023


Gasbagger
Gasbagger Sep. 13 at 4:27 PM
$OPK Opposition to Teva chairman's jet expenses. Some things never change. There is Nobody to stop Frost ,since he calls all the shots at Opko.
0 · Reply
tymtested
tymtested Sep. 12 at 7:53 PM
$OPK on equivalent daily average, opko buys back 150,000 shares or about 6% of the stock traded. Even more impactful when considering the float is about 50% of outstanding shares.
0 · Reply
Gasbagger
Gasbagger Sep. 12 at 7:44 PM
$OPK Speaking at the Wells Fargo Healthcare Conference, President and Vice Chairman Elias Zerhouni said,a GLP-1/glucagon candidate in Phase I development.**OPK-8801001**,is at the investigational new drug stage and expects to enter clinical trials in the following month.A **CAR-T program,** a first clinical trial is expected at the end of the year or early next year.MDX-2001,with potential results expected early next year.OPKO expects Merck to make a decision on how to proceed in the near term, he said.He added that OPKO expects to pursue additional partnerships because it does not intend to independently fund every program through later stages. In every statement Zerhouni made he said EXPECTS. That is not definite. So it seems everything has been at a standstill for quite sometime . So what has 35 MILLION in R&D every quarter being spent on ?
0 · Reply
tymtested
tymtested Sep. 12 at 7:23 PM
$OPK OPKO’s utilization of nondilutive financing is a good indication they believe stock price appreciation is near and frost didn’t want to dilute it. Also ,opko may want to run up the price fairly soon,(after they buyback) to use higher priced shares to buy COCP.
0 · Reply
tradertrash
tradertrash Sep. 11 at 8:30 PM
$OPK always tomorrow... for some reason 🙄 they never can deliver today❓ ray & hgh are successful, it's just sh never get to share in that success, but u can bet they never miss a raise or bonus or stock option, for a complete failure to sh, it's been years ive heard that tomorrow bs, they just keep funding, without showing any return for sh, gets old, same old sh*t, rinse & repeat
1 · Reply
tymtested
tymtested Sep. 11 at 7:24 PM
$OPK opko will retain 100% of its royalties on mazdutide once LLY launches mazdutide in other countries outside of china. HUGE coming opportunity!
0 · Reply
Gasbagger
Gasbagger Sep. 11 at 6:25 PM
$OPK Everything Opko has done has been a failure for Shareholders,but yet ,Frost and Friends keep reaping big pay days. From all of his self serving investments ,Cocp,Entx ,Vbiv,Shareholders never received ONE SHARE of anything. Frost now wants you to believe in ModeX as all the cash is disappearing.
0 · Reply
Sierradude
Sierradude Sep. 11 at 5:32 PM
$OPK 12.5 mil a year? At that rate they can pay their Israeli tax bill in 20 years.... don't piss on my back and tell me its raining.....
1 · Reply
tymtested
tymtested Sep. 11 at 4:52 PM
$OPK i just hope opko can complete the stock buyback at these low prices.
0 · Reply
tymtested
tymtested Sep. 11 at 4:50 PM
$OPK if opko were to announce that bioref labs were generating $12.5M earns annually the stock would probably explode!!whats the difference?!?
0 · Reply
tymtested
tymtested Sep. 11 at 4:49 PM
$OPK CFO stated the $125M deal based on mazdutide royalties were equivalent to ten years of royalties! That's $12.5M annually of new and previously unrecognized ongoing and growing continuous earnings stream!! EARNINGS! at a 30 pe, that should have generated at least a share price increase of $.50 to $1.00!! so its going to take the market a moment to wake up!! mazdutide is growing fast!!
0 · Reply
LongAllDay
LongAllDay Sep. 11 at 3:40 PM
$OPK frost had to smell bad, right?
0 · Reply
tradertrash
tradertrash Sep. 11 at 3:23 PM
$OPK p&dko
0 · Reply
tymtested
tymtested Sep. 11 at 12:46 AM
$OPK opko is buying back stock, so where would one guess they would want the stock price? The stock will move up when Opko wants it to move up. Meantime market gyrations will be the rule.
0 · Reply
TommyCotton
TommyCotton Sep. 10 at 10:15 PM
$OPK The biggest takeaway from OPKO’s Wells Fargo presentation is that ModeX is beginning to move from scientific promise toward human evidence. MDX2001 dose escalation is essentially complete, and management says some tumor types are clearly responding better than others. They now plan to focus on the two or three showing the strongest response. MDX2003 is showing B-cell depletion, while MDX2004 is showing encouraging immune-cell effects. Merck is analyzing its completed EBV Phase 1 trial and considering Phase 2. None of this proves clinical success yet, but importantly, the ModeX story is beginning to produce measurable signals in humans—not just promising laboratory science.
1 · Reply
tymtested
tymtested Sep. 10 at 9:15 PM
$OPK take your Trump dividend of $5000 and invest it in opko to become $10,000+!!! GO OPKO!!
0 · Reply
steviem
steviem Sep. 10 at 6:05 PM
$OPK It's official.....last Wednesday's phony pump is completely wiped out.....as usual.
0 · Reply
Mike18181
Mike18181 Sep. 10 at 5:19 PM
$OPK Insider trading, politics, and piwer have a seperate rulebook. " the untouchables". Pandemic , now 100+ oil. Recklass behaviour to stakeholders is also Frost. IMO Impeach trump and Netan-yahoo has shown his ASS. Hes all talk !
0 · Reply
magadog
magadog Sep. 10 at 4:01 PM
$OPK Never fails One of the original clowns shows up at some conference and, boom, reminds people how full of crap the company executives are
0 · Reply
Brasil07
Brasil07 Sep. 10 at 3:01 PM
$OPK if I should have Mr.Frost in my hands for 5 minutes.....
0 · Reply
Zerrat
Zerrat Sep. 10 at 2:50 PM
$OPK pump and dump; never changes
0 · Reply
steviem
steviem Sep. 9 at 8:19 PM
$OPK Drip, drip, drip.......OPK's speciality.
0 · Reply